Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
80 hedge funds and large institutions have $214M invested in Inozyme Pharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 9 closing their positions.
1,341% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $100K
180% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 15
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
4% more funds holding
Funds holding: 77 → 80 (+3)
2.34% more ownership
Funds ownership: 78.93% → 81.27% (+2.3%)
4% more capital invested
Capital invested by funds: $205M → $214M (+$9.18M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$4.51M |
| 2 |
BlackRock
New York
|
+$2.85M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$1.8M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.17M |
| 5 |
Goldman Sachs
New York
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$3.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.94M |
| 3 |
Millennium Management
New York
|
-$1.48M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$722K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$685K |
INZY Hedge Fund Activity: Q4 2023 in Review
80 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2023, worth a combined $214M — up 4.5% from $205M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new INZY positions and 9 closed out — a net gain of 4 holders — while 42 added to existing stakes and 15 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $4.51M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.2M.
- 80 institutional investors held Inozyme Pharma (INZY) as of Q4 2023, up from 77 in Q3 2023.
- Funds reported $214M of Inozyme Pharma stock for Q4 2023, up 4.5% quarter-over-quarter.
- 13 funds opened new Inozyme Pharma positions in Q4 2023 and 9 closed out, a net change of +4 holders.
- The largest Inozyme Pharma buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $4.51M added.
- The largest Inozyme Pharma seller in Q4 2023 was Octagon Capital Advisors, an estimated $3.2M sold.
Based on aggregated 13F filings for Q4 2023.